FAVIPIRAVIR – PATENT ANALYSIS REPORT

07 May FAVIPIRAVIR – PATENT ANALYSIS REPORT

Posted at 03:31h in US Patent by utkan

CAS Number: 259793-96-9
Synonyms: T-705, 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide
Innovator/Originator: Toyama Chemical (Fujifilm group)
Brand Name: Avigan
Pharmaceutical form & strength: Oral tablet formulation, 200MG
Marketing authorisation holder: Fujifilm Corporation
Marketing Status: Authorised in Japan
Approval Date: March 2014
Approved Therapeutic Indication: Infectious disease; Influenza virus infection

On March 31, Fujifilm announced the start of a phase III clinical trial of Avigan for COVID-19 patients in Japan.
Fujifilm announces the start of a phase II clinical trial of its influenza antiviral drug “Avigan® Tablet” for COVID-19 patients in the U.S on April 9, 2020.

Raporun tamamı için : PATENT ANALYSIS REPORT – FAVIPIRAVIR